Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.38 USD | -1.65% | -5.93% | +2.15% |
05/06 | VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 | CI |
09/05 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.15% | 3.46Cr | |
+42.69% | 75TCr | |
+38.19% | 61TCr | |
-6.87% | 35TCr | |
+18.74% | 33TCr | |
+6.76% | 29TCr | |
+18.36% | 25TCr | |
-3.48% | 21TCr | |
+10.88% | 22TCr | |
+2.64% | 17TCr |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- Transcript : Menlo Therapeutics Inc. - Analyst/Investor Day